Clinical characteristics and outcomes of hematogenous vertebral osteomyelitis caused by gram-negative bacteria
- Authors
- Park, Ki-Ho; Cho, Oh Hyun; Jung, Myounghwa; Suk, Kyung-Soo; Lee, Jung Hee; Park, Ji Seon; Ryu, Kyung Nam; Kim, Sung-Han; Lee, Sang-Oh; Choi, Sang-Ho; Bae, In-Gyu; Kim, Yang Soo; Woo, Jun Hee; Lee, Mi Suk
- Issue Date
- Jul-2014
- Publisher
- W B SAUNDERS CO LTD
- Keywords
- Vertebral osteomyelitis; Spondylitis; Spondylodiscitis; Gram-negative bacteria; Outcome
- Citation
- JOURNAL OF INFECTION, v.69, no.1, pp 42 - 50
- Pages
- 9
- Indexed
- SCI
SCIE
SCOPUS
- Journal Title
- JOURNAL OF INFECTION
- Volume
- 69
- Number
- 1
- Start Page
- 42
- End Page
- 50
- URI
- https://scholarworks.gnu.ac.kr/handle/sw.gnu/18902
- DOI
- 10.1016/j.jinf.2014.02.009
- ISSN
- 0163-4453
1532-2742
- Abstract
- Objective: To evaluate the clinical characteristics and outcomes of patients with hematogenous vertebral osteomyelitis (HVO) caused by gram-negative bacteria (GNB). Methods: We conducted a retrospective chart review of adult patients with HVO from three tertiary-care hospitals over a 7-year period. Results: Of the 313 microbiologically diagnosed HVO cases, GNB was responsible for 65 (20.8%) cases. Compared with patients with MSSA HVO, patients with GNB HVO were more likely to be female (P = 0.03) and have diabetes (P = 0.03), but less likely to have epidural abscess (P = 0.02) and paravertebral abscess (P = 0.003). Clinical outcomes were similar between the GNB and MSSA groups, including in-hospital mortality (4.6% vs. 7.8%; P = 0.53), recurrence (9.7% vs. 4.3%; P = 0.20), and sequelae (31.7% vs. 32.2%; P = 0.95). Among GNB-infected patients, recurrence rates differed according to the total duration of antibiotic treatment: 40.0% (4-6 weeks), 33.3% (6-8 weeks), and 2.1% (>= 8 weeks) (P = 0.002). Conclusions: GNB HVO was responsible for 20.8% of adult cases of HVO. Despite some differences in clinical and radiological presentation, clinical outcomes were similar between GNB and MSSA HVO. Antibiotic therapy for >= 8 weeks may benefit patients with GNB HVO. (C) 2014 The British Infection Association. Published by Elsevier Ltd. All rights reserved.
- Files in This Item
- There are no files associated with this item.
- Appears in
Collections - College of Medicine > Department of Medicine > Journal Articles

Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.